DPYD overview- Pharmaco genetic test

Question 1

With DPYD, what are we analyzing?

Answer 1

DNA, DPYD genes and testing for 5 alleles, variants etc… in the DPYD gene.

Question 2

Is this an add-on to xT?

Answer 2

Yes

Question 3

What has to be submitted with this to get results?

Answer 3

The “normal match” because it’s a germline test.

Question 4

What will this test tell us?

Answer 4

identifies potential toxicity to 5-FU and capecitabine (two most common drugs for chemo) We are testing to see if the patient has toxicity to these two drugs.

Question 5

which organizations guidelines do NOT indicate DPYD gene analysis should be performed prior to administering 5-FU or Cap?

Answer 5

FDA

Question 6

what are the three different phenotypic classifications which could appear as a result on a DPYD report?

Answer 6

1. Intermediate metabolizer, has increased risk to 5-FU and Cap.
2. The CORE metabolizers could have a fatal reaction. An estimated .1% of patients will be recognized as “Core metabolizers”
3. Normal, meaning we did not detect any variants. They aren’t at an increased risk.

Question 7

which clinicians should DPYD testing potentially be discussed with?

Answer 7

Any doctor who administers these drugs.